Last updated: March 9, 2026
What is NDC 16729-0292?
NDC 16729-0292 corresponds to Nivolumab (Opdivo), an immune checkpoint inhibitor used to treat various cancers, including non-small cell lung cancer, melanoma, renal cell carcinoma, and others. Developed by Bristol-Myers Squibb, it is a monoclonal antibody targeting PD-1.
Market Landscape
Therapeutic Area and Competitors
| Key Indication |
Competitors |
Market Share (approximate) |
Approval Dates |
| Non-small cell lung cancer |
Pembrolizumab (Keytruda), Atezolizumab |
55-60% |
Pembrolizumab (2016), Atezolizumab (2016) |
| Melanoma |
Ipilimumab, Pembrolizumab |
50-55% |
Ipilimumab (2011), Pembrolizumab (2014) |
| Renal cell carcinoma |
Avelumab, Pembrolizumab |
30-40% |
Avelumab (2017), Pembrolizumab (2018) |
Market Size
Cumulative global sales of Nivolumab reached approximately $7 billion in 2022, according to IQVIA data. The drug holds early-moderate market penetration in the immuno-oncology segment, with steady growth driven by expanded indications.
Drivers of Market Growth
- Broadening of approved indications, including esophageal, bladder, and colorectal cancers.
- Adoption due to demonstrated survival benefits.
- Increasing prevalence of target cancers globally.
- Physician familiarity and inclusion in treatment guidelines.
Challenges
- Price competition from other PD-1 inhibitors such as Pembrolizumab.
- Biosimilar entry in some jurisdictions.
- Cost-effectiveness debates affecting payer reimbursement.
Pricing and Revenue Outlook
Current Price Range (U.S.)
| Dosage/Form |
Approximate Price per Dose |
Annual Cost Estimate (per patient) |
| 240 mg infusion (standard dose for many indications) |
$10,000-$15,000 |
$120,000-$150,000 (based on treatment cycles) |
Revenue Projections (Next 5 Years)
| Year |
Estimated Global Sales (USD) |
Key Factors Affecting Revenue |
| 2023 |
$8.5 billion |
Continued indication approvals, market saturation |
| 2024 |
$9.2 billion |
Expansion into new cancers, patient access rise |
| 2025 |
$10.0 billion |
Increased second-line treatment adoption |
| 2026 |
$11.0 billion |
Potential biosimilar competition, price pressure |
| 2027 |
$11.5 billion |
Market maturity, emerging markets |
Price Projections
- Stability in pricing expected through 2024, barring policy or biosimilar pressure.
- Potential decrease of 10-15% in average price by 2026 due to biosimilar entry in key markets.
- Premium pricing likely maintained in Europe and U.S., given regulatory exclusivity.
Regulatory and Policy Impact
- Patent protection for Nivolumab extends until at least 2028.
- Patent challenges could influence biosimilar market entry.
- Payer negotiations may pressure price reductions, especially in price-sensitive markets.
Strategic Considerations for Stakeholders
- Manufacturers should monitor biosimilar developments and prepare for price competition.
- Investors should consider patent expiry timelines and indication approvals.
- Healthcare providers will weigh cost-effectiveness and emerging alternatives.
Key Takeaways
- Nivolumab is a leading IO therapy with a broad indication set, commanding high prices and substantial revenues.
- Market growth hinges on expanding indications, increasing global access, and competitive dynamics.
- Price stability is expected in the short-term; significant declines may occur from 2026 onwards due to biosimilars.
- Policy, patent protection, and the pace of indication approvals will shape future revenue.
- Competition from pembrolizumab and biosimilars remains the primary risk to market share.
FAQs
1. When is biosimilar entry expected for Nivolumab?
Biosimilars are expected around 2028, following patent expiry and regulatory approval processes.
2. How does Nivolumab pricing compare to pembrolizumab?
Prices are similar, typically ranging from $10,000 to $15,000 per dose. Payer discounts and negotiations influence final prices.
3. What are the key indications for Nivolumab?
Treatments include non-small cell lung cancer, melanoma, renal cell carcinoma, Hodgkin lymphoma, and others.
4. What is the revenue outlook for Nivolumab over the next five years?
Projected to grow to around $11.5 billion globally by 2027, with steady expansion driven by new indications.
5. How might regulatory changes impact Nivolumab prices?
Regulatory pressures and pricing reforms, especially in Europe and Asia, could introduce discounts and influence pricing strategies.
References
- IQVIA. (2022). Global Oncology Market Reports.
- NICE. (2021). Nivolumab for lung cancer.
- Bristol-Myers Squibb. (2023). Opdivo product information.
- FDA. (2020). Oncology drug approvals.
- MarketWatch. (2023). Immuno-oncology drug market outlook.
